Cargando…
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
We investigated the prognostic value of the serum half-life of human chorionic gonadotrophin (HCG) and alpha-fetoprotein (AFP) during induction chemotherapy and the relative prognostic importance of initial marker concentrations and marker half-life. Marker half-lives were calculated using two abnor...
Autores principales: | de Wit, R., Sylvester, R., Tsitsa, C., de Mulder, P. H., Sleyfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Vermeylen, K., Stoter, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063372/ https://www.ncbi.nlm.nih.gov/pubmed/9020492 |
Ejemplares similares
-
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.
por: de Wit, R., et al.
Publicado: (1998) -
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
por: de Wit, R., et al.
Publicado: (1995) -
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
por: de Wit, R., et al.
Publicado: (1998) -
Semen quality from patients affected by seminomatous and non-seminomatous testicular tumor
por: Xavier, Rosana, et al.
Publicado: (2020) -
Distinct Proteomic Profile of Spermatozoa from Men with Seminomatous and Non-Seminomatous Testicular Germ Cell Tumors
por: Panner Selvam, Manesh Kumar, et al.
Publicado: (2020)